BICO strengthens IP Portfolio with Patents in the United States and Sweden for 3D bioprinting of Temperature Sensitive Bioinks
These innovations will allow for higher cell viability and better reproducibility when bioprinting temperature-sensitive bioinks such as collagen. Thus, accelerating scientific research and 3D cell-based assays for drug discovery and tissue engineering.BICO , the world’s leading bio convergence company, has been granted two patents relating to the regulation and precise control of bioink’s processing temperatures in 3D Bioprinters. The first patent, US 11,046,001